The growth of Molecular Quality Controls Market is primarily driven by factors such as the rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, the rising demand for external quality assessment support, increasing government funding to support genomics projects, increasing demand for personalized medicines and declining costs of sequencing procedures and increasing prevalence of infectious diseases, cancer & genetic diseases.
The molecular quality controls market size is expected to grow from USD 164 million in 2021 to USD
226 million by 2026, at a CAGR of 6.7% during the forecast period.
Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523
Market Segmentation:
Based on product, the molecular quality control market is
segmented into Independent Controls and Instrument Specific Controls. The
Independent control segment accounted for the largest share of the market in
2020. The increasing number of accredited laboratories and mandates for the use
of quality controls from regulatory bodies to ensure the accuracy of diagnostic
test results are driving the growth of the molecular quality control products
market.
Based on analyte type, the market is segmented into
single-analyte controls and multi-analyte controls. Single-analyte controls
dominated the molecular quality controls market in 2020 due to the significant
use of singleplex assays in hospitals and the advantages associated with the
use of single-analyte controls, such as simple analysis & interpretation
and low risk of cross-reactivity.
Based on application, the molecular quality control market is
segmented into infectious disease diagnostics, oncology testing, genetic
testing, and other applications. The infectious disease diagnostics segment
accounted for the largest share of the molecular quality controls market in
2020. The large share of this segment is attributed to the development of
advanced assays for infectious diseases, a significant increase in the
prevalence of infectious diseases, and the rising awareness about the effective
use of molecular diagnostic technologies to control the occurrence and spread
of infectious diseases.
The key end users of molecular quality controls studied in this
report include diagnostic laboratories, hospitals, IVD Manufacturers and CROs
Academic & Research Institutes, and other end users. The Diagnostic
Laboratories segment accounted for the largest share of the market in 2020,
increasing number of accredited diagnostic laboratories to provide growth
opportunities in the coming years.
Regional Analysis:
The molecular quality control market is segmented into five
major regions, namely, North
America, Europe, Asia Pacific, Latin
America, and the Middle
East & Africa.
In 2020, North America was
the largest regional market for molecular quality controls due to the developed
healthcare system in the US and Canada,
the presence of many leading molecular quality control product manufacturers in
the region, and the easy accessibility to technologically advanced products in
the region.
Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523
Top Key Players:
The prominent players in the molecular quality controls market
are F. Hoffmann-La Roche Ltd. (Switzerland),
Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox
Laboratories Ltd. (UK), LGC Limited (UK), Abbott Laboratories (US), Fortress
Diagnostics (UK), SERO AS (Norway),
Anchor Molecular (US), Ortho-Clinical Diagnostics, Inc. (US), Quidel
Corporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix, LLC (US), Qnostics (UK), Bio-Techne
Corporation (US), Microbiologics, Inc. (US), Microbix Biosystems Inc. (Canada), SpeeDx Pty. Ltd. (Australia),
Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).
No comments:
Post a Comment